Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis–associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects

Dypeptidylpeptidase-4 inhibitors and the cardiovascular system: How to manage the fil rouge

(2019) I. Dicembrini et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth

(2019) Clémence Hollande et al.   NATURE IMMUNOLOGY

Contribution of intestinal dipeptidyl peptidase-4 inhibition for incretin-dependent improved glucose tolerance in mice

(2019) Satoko Yamashita et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease

(2018) Eduardo Vilar-Gomez et al.   GASTROENTEROLOGY

C/EBPα-dependent preneoplastic tumor foci are the origin of hepatocellular carcinoma and aggressive pediatric liver cancer

(2018) Ashley Cast et al.   HEPATOLOGY

Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis

(2018) Toshihiro Goto et al.   Scientific Reports

Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH

(2018) Kumiko Shiba et al.   Scientific Reports

Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance

(2018) Devram S. Ghorpade et al.   NATURE

Circulating Levels of Soluble Dipeptidyl Peptidase-4 Are Dissociated from Inflammation and Induced by Enzymatic DPP4 Inhibition

(2018) Elodie M. Varin et al.   Cell Metabolism

Mouse models of nonalcoholic steatohepatitis Towards optimization of their relevance to human NASH

(2018) Geoff Farrell et al.   HEPATOLOGY

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis

(2018) Yuya Seko et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

A long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, as a preventive drug for the development of hepatic steatosis in high-fructose diet-fed ob/ob mice

(2017) Ken Nakamura et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice

(2017) Hotimah Masdan Salim et al.   VASCULAR PHARMACOLOGY

DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage Polarization

(2016) Fen Zhuge et al.   DIABETES

The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)

(2016) Elena Buzzetti et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

(2016) Teruo Jojima et al.   Diabetology & Metabolic Syndrome

Dipeptidyl Peptidase-4 Inhibition Ameliorates Western Diet–Induced Hepatic Steatosis and Insulin Resistance Through Hepatic Lipid Remodeling and Modulation of Hepatic Mitochondrial Function

(2015) Annayya R. Aroor et al.   DIABETES

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

(2015) Paul Angulo et al.   GASTROENTEROLOGY

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

(2015) Mattias Ekstedt et al.   HEPATOLOGY

DPP4 in diabetes

(2015) Diana Röhrborn   Frontiers in Immunology

Macrophage-inducible C-type lectin underlies obesity-induced adipose tissue fibrosis

(2014) Miyako Tanaka et al.   Nature Communications

Activating Transcription Factor 4 Links Metabolic Stress to Interleukin-6 Expression in Macrophages

(2013) Y. Iwasaki et al.   DIABETES

Dipeptidyl peptidase-4 inhibitor anagliptin ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet

(2013) Keizo Nakaya et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Hepatic Crown-Like Structure: A Unique Histological Feature in Non-Alcoholic Steatohepatitis in Mice and Humans

(2013) Michiko Itoh et al.   PLoS One

Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes

(2013) Lan He et al.   Journal of Diabetes Investigation

Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes

(2012) Y.-S. Lee et al.   DIABETOLOGIA

Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice

(2012) Dewei Ye et al.   GUT

Melanocortin 4 Receptor–Deficient Mice as a Novel Mouse Model of Nonalcoholic Steatohepatitis

(2011) Michiko Itoh et al.   AMERICAN JOURNAL OF PATHOLOGY

Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice

(2011) Timea Csak et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism

(2011) Masayuki Miyazaki   Molecular Medicine Reports

Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea

(2011) Yoshimasa Aso et al.   Translational Research

Diabetes and Cancer: A Consensus Report

(2010) E. Giovannucci et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Generalizability of the Nonalcoholic Steatohepatitis Clinical Research Network Histologic Scoring System for Nonalcoholic Fatty Liver Disease

(2010) Ravi Juluri et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes

(2007) Carolyn et al.   Frontiers in Bioscience-Landmark